Arthneeti
All Q2 FY26 results →
NF

NGL Fine Chem

Q2 FY26Pharmaceuticals & Biotechnology

NGL Fine Chem Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,948
Market cap₹2.1K Cr
P/E42.3
Updated23 Aug 2026
Read5 min read

The short version

Demand is currently strong and showing broad-based recovery across regions, especially in India and Asia Pacific. - Sales growth in the first half was about 22%, largely driven by volume growth, with export sales up 3-4% due to exchange rates and volume. - New plant commissioning in FY '27 aims to cater primarily to the U.S., EU, and higher-value markets like Latin America, expected to boost sales from regulated markets. - European sales are expected to reach around INR30 crores in the current fiscal year, with further ramp-up anticipated in FY '27, though exact forecasts are pending customer budgets. - U.S. The company expects sustained demand growth to continue over the next few quarters, indicating a positive outlook for revenue growth.

From NGL Fine Chem's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Demand is currently strong and showing broad-based recovery across regions, especially in India and Asia Pacific.
  • Sales growth in the first half was about 22%, largely driven by volume growth, with export sales up 3-4% due to exchange rates and volume.
  • New plant commissioning in FY '27 aims to cater primarily to the U.S., EU, and higher-value markets like Latin America, expected to boost sales from regulated markets.
  • European sales are expected to reach around INR30 crores in the current fiscal year, with further ramp-up anticipated in FY '27, though exact forecasts are pending customer budgets.
  • U.S. FDA approvals expected starting the second half of FY '27 should enable significant sales scale-up in the U.S. market.

2 more points from NGL Fine Chem's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what NGL Fine Chem said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing capital projects are on track for completion by Q4 FY '26, with commissioning scheduled for Q1 FY '27.
  • The new plant's first clean room under Phase 1 is already used for manufacturing validation batches.
  • The new plant is mainly for serving the U.S. and EU markets, plus higher-value areas like Latin America.
  • Some incremental operating expenses (INR1.2 to 1.5 crores per month) will arise post commissioning.
  • Capitalization includes interest and manpower costs directly involved in setting up the new plant; other related expenses are charged to P&L.
  • Peak long-term debt sanctioned for the project is INR95 crores, with expected actual utilization between INR75 to 95 crores.

2 more points from NGL Fine Chem's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not explicitly mention current or expected orderbook or pending orders in quantitative terms. However, some relevant points related to demand and order outlook are: - There is a strong improvement in demand across markets, including India and Asia, indicating a broad-based recovery. - The company experienced about 15%-20% outsourcing due to capacity constraints amid rising demand. - New plant commissioning in Q1 FY '27 is expected to enhance capacity specifically for the U.S., EU, and higher-value markets. - Regulatory approvals (e.g., first U.S. filing in September 2025) are expected to drive future sales growth.

2 more points from NGL Fine Chem's call on order book

Pro opens every point from 15K+ earnings calls

NGL Fine Chem — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

NGL Fine Chem and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were NGL Fine Chem Q2 FY26 results?

Demand is currently strong and showing broad-based recovery across regions, especially in India and Asia Pacific. - Sales growth in the first half was about 22%, largely driven by volume growth, with export sales up 3-4% due to exchange rates and volume. - New plant commissioning in FY '27 aims to cater primarily to the U.S., EU, and higher-value markets like Latin America, expected to boost sales from regulated markets. - European sales are expected to reach around INR30 crores in the current fiscal year, with further ramp-up anticipated in FY '27, though exact forecasts are pending customer budgets. - U.S. The company expects sustained demand growth to continue over the next few quarters, indicating a positive outlook for revenue growth.

What is NGL Fine Chem share price analysis?

NGL Fine Chem currently shows a neutral. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem planning capital expenditure?

Ongoing capital projects are on track for completion by Q4 FY '26, with commissioning scheduled for Q1 FY '27. - The new plant's first clean room under Phase 1 is already used for manufacturing validation batches. - The new plant is mainly for serving the U.S.

Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.